Last 37.20 INR
Change Today -0.65 / -1.72%
Volume 81.2K
PLEP On Other Exchanges
Symbol
Exchange
Natl India
As of 6:06 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

plethico pharmaceuticals ltd (PLEP) Snapshot

Open
37.65
Previous Close
37.85
Day High
39.75
Day Low
36.75
52 Week High
06/12/14 - 74.30
52 Week Low
12/17/14 - 35.40
Market Cap
1.3B
Average Volume 10 Days
50.6K
EPS TTM
36.01
Shares Outstanding
34.1M
EX-Date
09/22/11
P/E TM
1.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for PLETHICO PHARMACEUTICALS LTD (PLEP)

Related News

No related news articles were found.

plethico pharmaceuticals ltd (PLEP) Related Businessweek News

No Related Businessweek News Found

plethico pharmaceuticals ltd (PLEP) Details

Plethico Pharmaceuticals Limited engages in the manufacture, marketing, and distribution of pharmaceutical and allied healthcare products in the nutraceuticals and herbal segments in India and internationally. It provides nutraceutical products, such as dietary supplements under the Natrol brand; and sports nutrition products, including HSP protein supplement for enhanced training, Pro NOS whey protein, and Black Powder pre workout energy boosting formula, as well as Prolab and Coach’s Formula sports nutrition product. The company’s nutraceutical products also comprise flavored herbal teas under the Laci Le Beau brand; NuHair and Shen Min hair products containing a serum and vitamins targeted at combating hair loss; and Promensil for relief of menopause symptoms, as well as Trinovin for maintaining prostate and urinary health. In addition, it offers herbal healthcare products, including a range of herbal products for cough and sore throat in the drops, syrups, and lozenges forms under the Travisil brand; Mountain Herbz range of herbal medicines and supplements to treat high blood pressure, digestions, and aphrodisiacs; medicated lozenges sold under the Actifresh brand; Travopassit, an anti-stress product; and Byte and Myntz products. Further, the company provides anti-malarial, anti-tubercular, anti-infective, pain, cardiac, gastro, and cough and cold products. Plethico Pharmaceuticals Limited was founded in 1963 and is based in Mumbai, India.

Founded in 1963

plethico pharmaceuticals ltd (PLEP) Top Compensated Officers

Executive Chairman and Managing Director
Total Annual Compensation: 2.2M
Chief-Executive Officer, Whole-Time Director,...
Total Annual Compensation: 2.2M
Compensation as of Fiscal Year 2014.

plethico pharmaceuticals ltd (PLEP) Key Developments

Plethico Pharmaceuticals Limited Reports Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Plethico Pharmaceuticals Limited reported unaudited consolidated and standalone earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 475.494 million against INR 1,054.723 million a year ago. Profit from operation before other income, finance cost and exceptional items was INR 24.998 million against INR 159.392 million a year ago. Loss from ordinary activities before tax was INR 72.429 million against profit from ordinary activities before tax of INR 24.675 million a year ago. Net loss for the period was INR 72.429 million or INR 2.13 per diluted share (before and after ordinary items) against net profit for the period of INR 16.288 million or INR 0.48 per diluted share (before and after ordinary items) reported last year. For the nine months, on standalone basis, the company reported net sales/income from operations of INR 980.495 million against INR 2,359.046 million a year ago. Profit from operation before other income, finance cost and exceptional items was INR 33.729 million against INR 325.799 million a year ago. Loss from ordinary activities before tax was INR 180.238 million against profit from ordinary activities before tax of INR 77.454 million a year ago. Net loss for the period was INR 180.238 million or INR 5.29 per diluted share (before and after ordinary items) against net profit for the period of INR 43.796 million or INR 1.29 per diluted share (before and after ordinary items) reported last year. For the quarter, on consolidated basis, the company reported on consolidated basis net sales/income from operations of INR 2,605.026 million against INR 4,391.237 million a year ago. Profit from operation before other income, finance cost and exceptional items was INR 362.316 million against INR 468.903 million a year ago. Loss from ordinary activities before tax was INR 153.320 million against profit from ordinary activities before tax of INR 244.522 million a year ago. Net loss for the period was INR 63.075 million or INR 1.85 per diluted share (before and after ordinary items) against net profit for the period of INR 209.697 million or INR 6.16 per diluted share (before and after ordinary items) reported last year. For the nine months, on consolidated basis, the company reported net sales/income from operations of INR 5,361.576 million against INR 9,037.802 million a year ago. Profit from operation before other income, finance cost and exceptional items was INR 716.428 million against INR 1,160.891 million a year ago. Loss from ordinary activities before tax was INR 165.788 million against profit from ordinary activities before tax of INR 620.935 million a year ago. Net loss for the period was INR 798.838 million or INR 2.34 per diluted share (before and after ordinary items) against net profit for the 40period of INR 653.248 million or INR 19.19 per diluted share (before and after ordinary items) reported last year.

Plethico Pharmaceuticals Limited to Report Q2, 2015 Results on Nov 14, 2014

Plethico Pharmaceuticals Limited announced that they will report Q2, 2015 results on Nov 14, 2014

Plethico Pharmaceuticals Limited, Board Meeting, Nov 14, 2014

Plethico Pharmaceuticals Limited, Board Meeting, Nov 14, 2014. Agenda: To consider, approve and take on record the in-audited financial results of the company for the second quarter and half year ended September 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLEP:IN 37.20 INR -0.65

PLEP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.70 USD -0.02
Amway Malaysia Hldgs Bhd 10.50 MYR +0.10
Endo International PLC $72.10 USD +0.34
Kellogg Co $67.02 USD -0.22
Wyeth Ltd 1,334 INR 0.00
View Industry Companies
 

Industry Analysis

PLEP

Industry Average

Valuation PLEP Industry Range
Price/Earnings 5.3x
Price/Sales 0.1x
Price/Book 0.1x
Price/Cash Flow 1.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLETHICO PHARMACEUTICALS LTD, please visit www.plethico.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.